NCT06377852 2026-03-18
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
American Society of Clinical Oncology
Phase 3 Recruiting
Clinical Trials
9 trialsNCT06065748 2026-03-09
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Hoffmann-La Roche
Phase 3 Recruiting
NCT07174336 2026-03-06
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Eli Lilly and Company
Phase 3 Recruiting
NCT06760637 2026-03-02
FourLight-3
Pfizer
Phase 3 Recruiting
NCT04546009 2026-02-20
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT07405164 2026-02-12
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3 Not yet recruiting
NCT05501886 2026-02-10
VIKTORIA-1
Celcuity Inc
Phase 3 Active not recruiting
NCT05909397 2026-02-10
VERITAC-3
Pfizer
Phase 3 Active not recruiting
NCT07340658 2026-01-14
SIE-3
Rovi Pharmaceuticals Laboratories
Phase 3 Not yet recruiting